Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers.
暂无分享,去创建一个
[1] Durgaramani Sivadasan,et al. A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy , 2023, Frontiers in Pharmacology.
[2] Wajhul Qamar,et al. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer , 2023, Molecules.
[3] G. Zayed,et al. Gefitinib-loaded starch nanoparticles for battling lung cancer: Optimization by full factorial design and in vitro cytotoxicity evaluation , 2022, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[4] S. Alkahtani,et al. Amelioration of bioavailability through formulating and optimizing Azilsartan Entrapped nanostructured lipid carriers and its pharmacokinetic assessment , 2022, Journal of Drug Delivery Science and Technology.
[5] H. Popli,et al. Design-of-Experiments (DoE)-Assisted Fabrication of Quercetin-Loaded Nanoemulgel and Its Evaluation against Human Skin Cancer Cell Lines , 2022, Pharmaceutics.
[6] G. Aggarwal,et al. Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials. , 2022, Recent Patents on Anti-Cancer Drug Discovery.
[7] I. Jaiyesimi,et al. Therapeutic landscape of advanced HER2-positive breast cancer in 2022 , 2022, Medical Oncology.
[8] S. Beg,et al. Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: An application towards in vitro and ex vivo performance evaluation , 2022, Arabian Journal of Chemistry.
[9] Jian-Hua Fu,et al. Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node‐positive esophageal squamous cell carcinoma: Is oral chemotherapy promising? , 2022, Cancer medicine.
[10] Dinesh Nyavanandi,et al. Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles , 2022, Pharmaceutics.
[11] F. Alanazi,et al. Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line , 2022, AAPS PharmSciTech.
[12] Annu,et al. Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization , 2022, BioMed research international.
[13] E. Cobain,et al. Breast cancer management in 2021: A primer for the obstetrics and gynecology. , 2022, Best practice & research. Clinical obstetrics & gynaecology.
[14] K. Anand,et al. Preparation and Evaluation of Gefitinib Containing Nanoliposomal Formulation for Lung Cancer Therapy , 2022, BioNanoScience.
[15] Yosif Almoshari,et al. Nanostructured lipid carrier system: A compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery , 2022, Nanotechnology Reviews.
[16] D. Bhatt,et al. Development of novel lipid matrix for improved sustained release effect of a hydrophilic drug via response surface methodology , 2021, Journal of Drug Delivery Science and Technology.
[17] David J Brayden,et al. Formulation strategies to improve the efficacy of intestinal permeation enhancers. , 2021, Advanced drug delivery reviews.
[18] Mohammed Elmowafy,et al. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies , 2021, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[19] Ajazuddin,et al. Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[20] J. Magaña,et al. Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses , 2021, Materials.
[21] O. Cevik,et al. Long chain fatty acids can form aggregates and affect the membrane integrity. , 2021, Colloids and surfaces. B, Biointerfaces.
[22] Gautam Singhvi,et al. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations , 2021, Drug Delivery and Translational Research.
[23] Jeonghee Cho,et al. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells , 2021, Cancers.
[24] R. Parton,et al. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics , 2021, Nature Nanotechnology.
[25] D. Acierno,et al. The universal usefulness of stearic acid as surface modifier: applications to the polymer formulations and composite processing , 2021 .
[26] M. El-Nabarawi,et al. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment , 2021, Drug delivery.
[27] Xiangrong Zhang,et al. Development and evaluation of puerarin-loaded controlled release nanostructured lipid carries by central composite design , 2020, Drug development and industrial pharmacy.
[28] Yuankai Shi,et al. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) , 2020, Journal of Hematology & Oncology.
[29] Bhupinder Singh,et al. QbD-steered development of Biotin-Conjugated Nanostructured Lipid Carriers for Oral Delivery of Chrysin: Role of Surface Modification for Improving Biopharmaceutical Performance. , 2020, Colloids and surfaces. B, Biointerfaces.
[30] Pankaj Kumar,et al. Lipid-nanopotentiated combinatorial delivery of tamoxifen and sulforaphane: ex vivo, in vivo and toxicity studies. , 2020, Nanomedicine.
[31] N. M. Raghavendra,et al. Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis , 2020 .
[32] E. M. Danielsen,et al. Intestinal permeation enhancers: Lessons learned from studies using an organ culture model. , 2020, Biochimica et biophysica acta. Biomembranes.
[33] Steven Abbott,et al. Solubility, similarity, and compatibility: A general-purpose theory for the formulator , 2020 .
[34] A. Kadi,et al. EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and In Vitro Rat Studies. , 2020, Chemical research in toxicology.
[35] K. Kohli,et al. PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment , 2020 .
[36] N. Dudhipala,et al. Enhanced pharmacokinetic activity of Zotepine via nanostructured lipid carrier system in Wistar rats for oral application. , 2020, Pharmaceutical nanotechnology.
[37] S. Mohan,et al. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro , 2020, Drug delivery.
[38] Sajjad Karim,et al. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. , 2019, Seminars in cancer biology.
[39] Annu,et al. Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies. , 2019, Journal of pharmaceutical sciences.
[40] Bhupinder Singh,et al. Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. , 2019, Colloids and surfaces. B, Biointerfaces.
[41] R. B. Walker,et al. Short Term Stability Testing of Efavirenz-Loaded Solid Lipid Nanoparticle (SLN) and Nanostructured Lipid Carrier (NLC) Dispersions , 2019, Pharmaceutics.
[42] K. Kohli,et al. Nanostructured Lipid Carriers for oral bioavailability enhancement of Exemestane: Formulation design, in vitro, ex vivo and in vivo studies. , 2019, Journal of pharmaceutical sciences.
[43] F. Wang,et al. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound. , 2019, Colloids and surfaces. B, Biointerfaces.
[44] S. Majumdar,et al. Curcumin-loaded Nanostructured Lipid Carriers for Ocular Drug Delivery: Design Optimization and Characterization. , 2018, Journal of drug delivery science and technology.
[45] Vieri Piazzini,et al. Nanostructured Lipid Carriers as Promising Delivery Systems for Plant Extracts: The Case of Silymarin , 2018, Applied Sciences.
[46] R. Saha,et al. Nanostructured lipid carriers for site-specific drug delivery. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[47] N. Jawahar,et al. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. , 2018, International journal of biological macromolecules.
[48] A. Ahad,et al. Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box–Behnken design , 2018 .
[49] O. Abdallah,et al. Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: Optimization and pharmacokinetics. , 2018, International journal of pharmaceutics.
[50] A. Beloqui,et al. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs , 2017 .
[51] H. Mahajan,et al. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study , 2016, Drug delivery.
[52] M. Blanco-Prieto,et al. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[53] G. Zhai,et al. Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation , 2015 .
[54] V. Pokharkar,et al. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[55] Han‐Gon Choi,et al. Preparation and Characterization of Fenofibrate-Loaded Nanostructured Lipid Carriers for Oral Bioavailability Enhancement , 2014, AAPS PharmSciTech.
[56] Swati S. Korabu,et al. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. , 2014, Colloids and surfaces. B, Biointerfaces.
[57] S. Nonen,et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. , 2013, Clinical lung cancer.
[58] M. Shahedi,et al. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules , 2013 .
[59] R. Tan,et al. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[60] M. H. Santana,et al. Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery , 2011, Journal of drug delivery.
[61] R. Müller,et al. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.